Close
Almac
Achema middle east

News

Algeria Showcases its Strength in African Pharma Sector

Abdelmadjid Tebboune, the Algerian president, went on to address participants at the African Ministerial Conference on Local Pharmaceutical Production and Health Technologies on November 27, 2025, with his message being read by Sifi Ghrieb, the prime minister. The event, which...

The Future of Health and Wellbeing: A Market on the Rise

The health and wellbeing market has experienced significant growth over the past decade, driven by an increasing awareness of physical and mental health issues. As we look to the future, projections suggest that this trend will continue, with the...

Synthetic Drugs: A Growing Crisis or Signs of Improvement?

The landscape of drug usage has undergone significant changes in recent years, particularly with the rise of synthetic drugs. These substances, often engineered to mimic the effects of traditional illicit drugs, have raised alarm bells among health officials and...

Eli Lilly Becomes the First Drugmaker to Hit $1tn Valuation

Eli Lilly, the US pharma giant, has become the first drugmaker to hit $1tn valuation on November 22, 2025, hence entering the exclusive club, which is so far dominated by technology giants, highlighting its rise as a weight-loss powerhouse. The...

400 Global Regulatory Manufacturing Approvals for Samsung Biologics

Samsung Biologics announced on November 26, 2025, that it has gone on to achieve a whopping 400 regulatory manufacturing approvals all over the world due to its quality competitiveness. It is worth noting that as of November 2025, Samsung Biologics has secured...

Clinical Trial Services and the Role of a European CRO

Conducting a clinical trial today requires coordinated procedures, standardized documentation, and a clear understanding of the regulatory systems that govern research. As more studies extend across borders, the need for organizations with regional expertise becomes increasingly important. A European...

AstraZeneca, Biopharma Giant, Announces $2bn Investment in Maryland

It should not be termed as an overstatement when we say that Maryland is fast becoming the home away from home when it comes to AstraZeneca, the British drugmaker. On November 21, the biopharma powerhouse pushed it up a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »